Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Atrial Topology for a Unified Understanding of Typical and Atypical Flutter.
Duytschaever M, Van den Abeele R, Carlier N, Bezerra AS, Verstraeten B, Lootens S, Desplenter K, Okenov A, Nezlobinsky T, Shah D, Haas A, Luik A, Martens J, El Haddad M, De Smet M, De Becker B, Francois C, Le Polain de Waroux JB, Tavernier R, Knecht S, Hendrickx S, Vandersickel N. Duytschaever M, et al. Among authors: hendrickx s. Circ Arrhythm Electrophysiol. 2024 Nov;17(11):e013102. doi: 10.1161/CIRCEP.124.013102. Epub 2024 Nov 5. Circ Arrhythm Electrophysiol. 2024. PMID: 39498566 Free article.
Discovery of a Series of Macrocycles as Potent Inhibitors of Leishmania Infantum.
Riu F, Ruppitsch LA, Duy Vo D, Hong RS, Tyagi M, Matheeussen A, Hendrickx S, Poongavanam V, Caljon G, Sheikh AY, Sjö P, Kihlberg J. Riu F, et al. Among authors: hendrickx s. J Med Chem. 2024 Oct 24;67(20):18170-18193. doi: 10.1021/acs.jmedchem.4c01370. Epub 2024 Oct 8. J Med Chem. 2024. PMID: 39378318 Free PMC article.
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.
Fong Y, Dang L, Zhang B, Fintzi J, Chen S, Wang J, Rouphael NG, Branche AR, Diemert DJ, Falsey AR, Losada C, Baden LR, Frey SE, Whitaker JA, Little SJ, Kamidani S, Walter EB, Novak RM, Rupp R, Jackson LA, Yu C, Magaret CA, Molitor C, Borate B, Babu TM, Kottkamp AC, Luetkemeyer AF, Immergluck LC, Presti RM, Bäcker M, Winokur PL, Mahgoub SM, Goepfert PA, Fusco DN, Atmar RL, Posavad CM, Mu J, Makowski M, Makhene MK, Nayak SU, Roberts PC, Follmann D, Gilbert PB; Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team. Fong Y, et al. Clin Infect Dis. 2024 Sep 26:ciae465. doi: 10.1093/cid/ciae465. Online ahead of print. Clin Infect Dis. 2024. PMID: 39325506
Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial.
Evering TH, Moser C, Jilg N, Ritz J, Wohl DA, Li JZ, Margolis D, Javan AC, Eron JJ, Currier JS, Daar ES, Smith DM, Hughes MD, Chew KW; ACTIV-2/A5401 Study Team. Evering TH, et al. EClinicalMedicine. 2024 Aug 16;75:102787. doi: 10.1016/j.eclinm.2024.102787. eCollection 2024 Sep. EClinicalMedicine. 2024. PMID: 39252866 Free PMC article.
111 results